Recent progress on anticancer candidates in patents of herbal medicinal products

Recent Patents on Food, Nutrition and Agriculture

Volumn 3, Issue 1, 2011, Pages 30-48

  Feng, Yibin ^a   Wang, Ning ^a   Zhu, Meifen ^a   Feng, Yigang ^b   Li, Hongyun ^b   Tsao, Saiwah ^c  

^a THE UNIVERSITY OF HONG KONG   (Hong Kong)

^b SUN YAT SEN UNIVERSITY   (China)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Anticancer drugs; Antimetastasis drugs; Chinese medicines; Complementary and alternative medicines; Herbal medicine; Patent

Indexed keywords

ANTINEOPLASTIC AGENT; PLANT EXTRACT;

ANIMAL; DIET SUPPLEMENTATION; DRUG DEVELOPMENT; HUMAN; NEOPLASM; PATENT; PHYTOTHERAPY; REVIEW; UNITED STATES;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DIETARY SUPPLEMENTS; DRUG DISCOVERY; HUMANS; NEOPLASMS; PATENTS AS TOPIC; PHYTOTHERAPY; PLANT EXTRACTS; UNITED STATES;

EID: 79955007154     PISSN: 22127984     EISSN: 18761429     Source Type: Journal    
DOI: 10.2174/2212798411103010030     Document Type: Review

References (111)

1. Cragg GM, Newman DJ. Plants as a source of anti-cancer agents. J Ethnopharmacol 2005;100:72-9. (Pubitemid 41073525)
2. Weiss RA, McMichael AJ. Social and environmental risk factors in the emergence of infectious diseases. Nat Med 2004;10:S70-6. (Pubitemid 40018229)
3. Tang J, Feng Y, Tsao S, Wang N, Curtain R, Wang Y. Berberine and Coptidis rhizoma as novel antineoplastic agents: A review of traditional use and biomedical investigations. J Ethnopharmacol 2009;126:5-17.
4. Tsang CM, Echo L P W, Di K, Cheung PY, Hau PM, Ching YP, et al. Berberine inhibits RhoGTPases and cell migration at low doses but induces G2 arrest and apoptosis at high doses in human cancer cells. Int J Mol Med 2009;24:131-8.
5. Wang N, Feng Y, Lau PW, Tsang CM, Ching YP, Man K, et al. F-actin reorganization and inactivation of Rho signaling pathway involved in the inhibitory effect of Coptidis rhizoma on hepatoma cell migration. Integr Cancer Ther (In press).
6. Wang N, Feng Y, Zhu M, Tsang CM, Man K, Tong Y, et al. Berberine induces autophagic cell death and mitochondrial apoptosis in liver cancer cells: The cellular mechanism. J Cell Biochem 2010 [Epub ahead of print].
7. Maung, T. W. Berberine as a selective lung cancer agent. US20070298132 (2007)
8. Chan, P. K., Mak, M. S., Wang, Y. Anticancer biangeloyl saponins. US7514412 (2009)
9. Ikekawa, T., Ikekawa, N. Carcinostatic compound and production thereof. US5616609 (1997).
10. Han, Q. B, Song, J. Z., Qiao, C. F., Yang, L., Xu, H. X. Compounds from Garcinia hanburyi, their use in treating cancer and method of separating epimers thereof. US7592367 (2009).
11. Aylward, J. H. Anti-cancer compounds. US6787161 (2004).
12. Khanuja S. P. S., Tiruppadiripuliyur, R. S. K. Gupta, V. K., Chand, P., Garg, A., Srivastava, S. K., Verma, S. C., Saikia, D., Darokar, M. P., Shasany, A. K., Pal, A. Antimicrobial and anticancer properties of methyl-beta- orcinolcarboxylate from lichen. US20070099993 (2007).
13. Zhang, M. Q., Sheridan R. M. 39-desmethoxyrapamycin, compositions and methods of use thereof. US7183289 (2007).
14. Hahm, J. C., Lee, D. S., Ko, J. P., Lee, I. K., Lee, H. W., Park, J. S. Pharmaceutical composition containing the extract of Saururus chinensis baill useful as an anticancer agent and a process for the preparation thereof. US20040024055 (2004).
15. Wang, L., Liu, X., Chen. R. Derivatives of isoindigo, indigo and indirubin and methods of treating cancer. US6933315 (2005).
16. Dai, D., Musser, J. H., Lennox. E. S. Triptolide derivatives for modulation of apoptosis and immunosuppression. US7662976 (2010).
17. Rosen, R. T. Ho, C. T., Dipaola, R. S., Rafi, M. M., Vastano, B. C., Ghai, G. Use of 1-propanone-1-(2, 4-dihydroxyphenyl)-3-hydroxy-3-(4'- hydroxyphenyl) as an anti-carcinogenic agent. US6498195 (2002).
18. Qazi, G. N., Taneja. S. C., Singh, J., Saxena, A. K., Sethi, V. K., Shah, B. A., Kapahi, B. K., Andotra, S. S., Kumar, A., Bhushan, S., Malik, F., Mondhe, D. M., Muthiah, S., Singh, S., Verma, M. Singh, S. K. Use of semi synthetic analogues of boswellic acids for anticancer activity. US20090298938 (2009).
19. Zhang, S., Bao, Y., Sun, Y., Li, K., Zou, L., Ma, J., Sun, X., Shang, H., Li, J. Cyclin-dependent protein kinases inhibitor of Scutellaria flavonoid organic amine derivatives, synthesis and use thereof. US20100197619 (2010).
20. 6) of a natural chemical substance and its pharmaceutical composition. US6589567 (2003).
21. Banerjee, P., Raja, K. S. Use of curcumin to block brain tumor formation in mice. US20100197584 (2010).
22. Dennis, J. W., Shah, R. N., Ziser, L. Alkaloid halide salts of swainsonine and methods of use. US6395745 (2002).
23. Shaheen PE, Stadler W, Elson P, Knox J, Winquist E, Bukowski RM. Phase II study of the efficacy and safety of oral GD0039 in patients with locally advanced or metastatic renal cell carcinoma. Invest New Drugs 2005;23:577-81. (Pubitemid 43162478)
24. Sun JY, Zhu MZ, Wang SW, Miao S, Xie YH, Wang JB. Inhibition of the growth of human gastric carcinoma in vivo and in vitro by swainsonine. Phytomedicine 2007;14:353-9. (Pubitemid 46654787)
25. Sun JY, Yang H, Miao S, Li JP, Wang SW, Zhu MZ, et al. Suppressive effects of swainsonine on C6 glioma cell in vitro and in vivo. Phytomedicine 2009;16:1070-74.
26. Cohen, I. Anticancer methods using extracts of Anemarrhena asphodeloides bunge. US20100009017 (2010).
27. Fabre, P., Raynaud, J. P., Cousse, H. Use of a Serenoa repens extract for the production of a medicament to treat prostate cancer. US6599540 (2003).
28. Mitra, S. K., Saxena, E., Dixit, M. N., Uddagiri, V. B., Marikunte, V. R., Mathad, S. A., Shanbhag, S. V. Novel anticancer agent, methods for obtaining the same and pharmaceutical compositions hereof. US20080199550 (2008).
29. Cohen, I. Anticancer methods employing extracts of Gleditsia sinensis lam. US20090258096 (2009).
30. Kuok, K. Y., Ly, H. Herbal compositions for prostate conditions. US6790464 (2004).
31. Choi, W. C., Park, S. J., Kwon, S. P. Process for preparation of Rhus verniciflua extracts having excellent anti-cancer activity and anticancer pharmaceutical composition containing the same. US7618661 (2009).
32. Bassa, B. V. Antitumor agent. US6660309 (2003).
33. Arellano, E. C. Anti-prostate cancer composition and therapeutic uses therefor. US7250180 (2007).
34. Ryu, S. Y., Lee, C. O., Choi, S. U., Park, S. H., Kim, Y. S., Kim, S. K., Kim, S. K., Kang, S. K. Anticancer composition comprising sesquiterpenes isolated from Resina ferulae. US20040043083 (2004).
35. Lin, C. H. Euphorbia antiquorum extract, a pharmaceutical composition containing the same and methods for treatment of cancers. US20030165579 (2003).
36. Rao, J. M., Srinivas, P. V., Yadav, J. S., Raghavan, K. V., Saxena, A. K., Shamugavel, H., Qazi, G. N. Herbal chemical composition for the treatment of cancer. US7285571 (2007).
37. Kuo, K. W. Water soluble extract from plant of Solanum genus and the preparation process thereof, and pharmaceutical composition containing the water soluble extract. US7078063 (2006).
38. Lee, S. H., Lee, Y. C., Jun, Y. C., Seo, J. K., Noh, J. S. Medicines manufactured from old platycodon extracts. US6902748 (2005).
39. Wu, R. T. Polysaccharide-based extract from Ganoderma, pharmaceutical use thereof, and process for preparing the same. US6613754 (2003).
40. Huang, M. T., Ho, C. T., Rosen, R. T., Ghai, G., Lipkin, M., Chen, K. Y., Telang, N., Boyd, C., Csiszar, K. Extracts of orange peel for prevention and treatment of cancer. US7201928 (2007).
41. Chu, K. H. Method of inducing apoptosis in cancer treatment by using Cucubritacins. US20080207578 (2008).
42. Shyur, L. F., Yang, N. S., Kang, P. L., Sun, S. J., Wang, S. Y. Use of Anoectochilus formosanus plant extracts and their derived fractions as herbal medicines or nutraceutical supplements for chemoprevention or treatment of human malignancies. US7033617 (2006).
43. Saxena, A. K., Gupta, B. D., Kapahi, B. K., Muthiah, S., Mondhe, D. M., Baleshwar, N., Qazi, G. N., Kumar, V., Mathan, G. Pharmaceutical composition useful for the treatment of hepatocellular carcinoma. US20060280817 (2006).
44. Kwon, B. M., Son, K. H., Han, D. C., Kim, J. H., Kang, H. M., Jeon, S. B. Artemisolide compound isolated from the aerial parts of Artemisia sylvatica, isolation method, and use thereof. US6808724 (2004).
45. Bandyopadhyay, S. Roy, K. C., Ray, M., Banerjee, G., Pal, B. C., Biswas, T., Bhattacharya, S. Herbal composition for treating CD33+ acute and chronic myeloid leukemia and a method thereof. US7306817 (2007).
46. Wang, Z. P. Saponins as anticancer agent. US20050175623 (2005).
47. Pei, H., Guo, Q., Chen, B, Zhu, H. Fagopyrum cymosum (Trev.) Meisn composition, method to prepare and analyze the same and uses thereof. US 6451353 (2002).
48. Joshi, K. S., Wagh, V., Sharma, S. Herbal composition and process for its preparation. US20100028472 (2010).
49. Mukherjee, R., Khattar, D., Jaggi, M., Singh, A. T., Kumar, M., Bala, H. Method for treating cancer using betulinic acid rich herbal extract. US20040116394 (2004).
50. Kwak, T. H., Shin, M. S., Kim, J. Y., Park, J. K. Active fraction having anti-cancer and anti-metastasis isolated from leaves and stems of ginseng. US20060034951 (2006).
51. Kim, M. Y. Composition comprising Melissa leaf extract for antiangiogenic and matrix metalloproteinase inhibitory activity. US20040009244 (2004).
52. Greenway, F. L. Angiogenic agents from plant extracts, gallic acid, and derivatives. US7709031 (2010).
53. Page, T. K. Herbal formulation. US6649185 (2003).
54. Kass, H. D., Freeman, A., Leyva, A. Natural composition extracted from plants used in the treatment of cancer. US5876728 (1999).
55. Sun, A. S. Herbal treatment of malignancy. US5437866 (1995).
56. Coe, S. D. Composition having anticancer activity. US6936284 (2005).
57. Zee, O. P., Kang, S. C., Kwak, J. H., Oh, J. S., Choi, H., Bak, J. P., Lee, C. M., Cheong, Y. J. Anti-cancer activity of Androsace umbellata merr. extract and contained triterpene saponin. US20080280839 (2008).
58. Managoli, N. Herbo-mineral formulation for refractory leukemias and lymphomas. US20050058722 (2005).
59. Hsieh, C. F. Herbal composition for treating cancer. US20070082072 (2007).
60. Dao, J., Dao, T. C. S., Tong, D. D., Wilson, L., Jordan, M. A., Gerwick, W. Compositions of botanical extracts for cancer therapy. US20050208070 (2005).
61. Newmark, T., Newman, R., Yang, P., Schulick, P. Methods for treating oral cancers with herbal compositions. US20080233218 (2008).
62. Kwon, B. M., Son, K. H., Han, D. C., Kho, Y. H., Chun, H. K., Kim, H. M., Lee, C. W. Pharmaceutical composition for treating and preventing cancer comprising cinnamoni cortex extract and Zizyphi fructus extract. US20070160691 (2007).
63. Solanki, R. Composition of eleven herbals for treating cancer. US6780441 (2004)
64. Karl Tsim, W. K., Li, X. Y. Herbal compositions useful in cancer treatment. US20060216366 (2006).
65. Cohen, I. Anti-cancer threapy with an extract of Scutellria barbata. US20090130101 (2009).
66. Omer, H. A. Preparation of Artemisia to treat human cancer, autoimmune disease, IgA-Nephropathy, and to counteract weight loss in cancer patients. US20080311230 (2008).
67. Einbond, L. S. Anti-neoplastic compositions comprising extracts of black cohosh. US7407675 (2008).
68. Shan, J. J., Pang, P. K. T., Huang, B., Ling, L. Processes of making north american ginseng fractions, products containing them, and use as immunomodulators. US6432454 (2002).
69. Morré, J. D. Compositions and methods based on synergies between capsicum extracts and tea catechins for prevention and treatment of cancer. US7192612 (2007).
70. Takahata, K., Matsui, Y. Antialopecia agent. US6713093 (2004).
71. Jo, S. K., Kim, S. H., Yee, S. T., Park, H. R., Oh, H., Byun, M. W. Herbal composition for improving anticancer activity, immune response and hematopoiesis of the body, and protecting the body from oxidative damage, and the method of preparing the same. US20040197427 (2004).
72. Bui, C. V., Bui, C. Q. Nutraceutical for the prevention and treatment of cancers and diseases affecting the liver. US20080213386 (2008).
73. Cheng, Y. C., Liu, S. H. Herbal composition PHY906 and its use in chemotherapy. US7025993 (2006).
74. Qazi, G. N., Bedi, K. L., Johri, R. K., Tickoo, M. K., Tickoo, A. K., Sharma, S. C., Abdullah, S. T., Suri, O. P., Gupta, B. D., Suri, K. A., Satti, N. K., Khajuria, R. K., Singh, S., Khajuria, A., Kapahi, B. K. Bioavailability/bioefficacy enhancing activity of cuminum cyminum and extracts and fractions thereof. US20040052873 (2004).
75. Gokaraju, G. R., Gokaraju, R. R., D'Souza, C., Frank, E. Bioavailability/bio-efficacy enhancing activity of Stevia rebaudiana and extracts and fractions and compounds thereof. US20100112101 (2010).
76. Khanuja, S. P. S., Kumar, S., Arya, J. S., Shasany, A. K., Singh, M., Gupta, S. C., Darokar, M. P., Rahman, L. U. Composition comprising pharmaceutical/nutraceutical agent and a bio-enhancer obtained from Glycyrrhiza glabra. US20060057234 (2006).
77. Medenica, R. D. Use of nigella sativa to increase immune function. US5653981 (1997).
78. Qazi, G. N., Bedi, K. L., Johri, R. K., Tikoo, M. K., Tikoo, A. K., Sharma, S., Abdullah, T., Suri, O. P., Gupta, B. D., Suri, K. A., Satti, N. K., Khajuria, R. K. Bioavailability enhancing activity of Carum carvi extracts and fractions thereof. US20050214390 (2005).
79. Wang, F. P., Wang, L., Yang, J. S., Chen, D. L., Jian, X. X. Preparation and drug composition of bis-benzyl-isoquinoline class alkaloids. US6617335 (2003).
80. Pejaver, S, Puri, N., Muthukumaran, P., Chordia, L. Process for preparing pharmaceutical formulations using supercritical fluids. US20040202681 (2004).
81. Kim, D. Y., Bae, E. A, Han, M. J., Choo, M. K., Park, E. K., Park, J. H. Extract of processed Panax genus plant, the preparation method thereof, and compositions containing the same. US20030190378 (2003).
82. Lu, K. M. Fermented Panax notoginseng solution with anti-cancer effects and manufacture method thereof. US20080220100 (2008).
83. Taipei City Hospital. Compound herbal formula (TPE-1) for leukopenia and cancer-related fatigue in breast cancer patients with radiotherapy. NCT01142479 (2010).
84. National Center for Complementary and Alternative Medicine (NCCAM). Iscar for Supplemental Care in Stage IV Lung Cancer. NCT00079794 (2004).
85. National Cancer Institute (NCI). Boswellia Serrata and Standard Treatment or Standard Treatment Alone in Treating Patients Who Have Undergone Surgery and Radiation Therapy for Newly Diagnosed or Recurrent High-Grade Glioma. NCT00243022 (2005).
86. Yale University. A clinical study of PHY906 as a modulator of CPT-11 in patients with metastatic colorectal cancer. NCT00730158 (2008).
87. National Cancer Institute (NCI). Sho-Saiko-to following removal of liver cancer by embolization in treating patients with liver cancer that cannot be surgically removed. NCT00040898 (2002).
88. Memorial Sloan-Kettering Cancer Center. Safety and pharmacokinetics of Jin Fu Kang in Comb w/Docetaxel for patients w/Nonsmall cell lung cancer. NCT00260026 (2005).
89. National Center for Complementary and Alternative Medicine (NCCAM). Ginger control of chemotherapy induced nausea and vomiting. NCT00065221 (2003).
90. University of California, San Francisco. Combination chemotherapy after surgery with or without chinese herbal therapy to treat symptoms in women with breast cancer. NCT00028964 (2002).
91. National Cancer Institute (NCI). Survey of the use of alternative medical therapies in adult cancer patients enrolled in phase I clinical trials. NCT00001695 (1999).
92. University of California, San Francisco. Treatment of anal highgrade squamous intraepithelial lesions (HSIL) through use of a chinese herbal topical cream (AIJP). NCT00622440 (2008).
93. PhytoCeutica Study of Botanical. PHY906 plus capecitabine for advanced unresectable hepatocellular carcinoma. NCT00076609 (2004).
94. British Columbia Cancer Agency ACAPHA. In preventing lung cancer in former smokers with bronchial intraepithelial neoplasia. NCT00522197 (2007).
95. National Center for Complementary and Alternative Medicine (NCCAM). Pycnogenol for the treatment of lymphedema of the arm in breast cancer survivors. NCT00064857 (2003).
96. Columbia University. Siliphos in advanced hepatocellular carcinoma. NCT01129570 (2010).
97. Legacy Health System. Trial of blue citrus compared to placebo in patients receiving aromatase inhibitor therapy for estrogen receptor positive post-menopausal breast cancer. NCT00702858 (2008).
98. Lawson Health Research Institute. Angelica sinensis for the treatment of hot flashes in men undergoing lhrh therapy for prostate cancer. NCT00199485 (2005).
99. University of Missouri-Columbia. A safety study of lessertia frutescens in adults. NCT00376415 (2006).
100. Tata Memorial Hospital. Pilot study of curcumin formulation and ashwagandha extract in advanced osteosarcoma (OSCAT). NCT00689195 (2008).
101. Wang X, Chan AW. Challenges and patenting strategies for Chinese herbal medicine. Chin Med 2010;5:24.
102. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod 2007;70:461-77. (Pubitemid 46595760)
103. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70. (Pubitemid 30046295)
104. Fong H. H. Integration of herbal medicine into modern medical practices: issues and prospects. Integr Cancer Ther 2002;1:287-93. (Pubitemid 37101735)
105. Tilton R, Paiva AA, Guan J, Marathe R, Jiang Z, van Eyndhoven W, et al. A comprehensive platform for quality control of botanical drugs (PhytomicsQC): a case study of Huangqi Tang (HQT) and PHY906. Chin Med 2010;5:30.
106. Ye M, Liu SH, Jiang Z, Lee Y, Tilton R, Cheng YC. Liquid chromatography/mass spectrometry analysis of PHY906, a Chinese medicine formulation for cancer therapy. Rapid Commun Mass Spectrom 2007;21:3593-607. (Pubitemid 350124627)
107. Zhang W, Saif MW, Dutschman GE, Li X, Lam W, Bussom S, et al. Identification of chemicals and their metabolites from PHY906, a Chinese medicine formulation, in the plasma of a patient treated with irinotecan and PHY906 using liquid chromatography/tandem mass spectrometry (LC/MS/MS). J Chromatogr A 2010;1217:5785-93.
108. Lam W, Bussom S, Guan F, Jiang Z, Zhang W, Gullen EA, et al. The four-herb Chinese medicine PHY906 reduces chemotherapyinduced gastrointestinal toxicity. Sci Transl Med 2010;2:45-59.
109. Saif MW, Lansigan F, Ruta S, Lamb L, Mezes M, Elligers K, et al. Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies. Phytomedicine 2010;17:161-9.
110. Yen Y, So S, Rose M, Saif MW, Chu E, Liu SH. Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma. Anticancer Res 2009;29:4083-92.
111. Eng C. Are herbal medicines ripe for the cancer clinic? Sci Transl Med 2010;2:45ps41.